HomeCompareMRK vs CQP

MRK vs CQP: Dividend Comparison 2026

MRK yields 2.81% · CQP yields 4.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CQP wins by $8.0K in total portfolio value
10 years
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →
CQP
CQP
● Live price
4.92%
Share price
$67.12
Annual div
$3.30
5Y div CAGR
25.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.7K
Annual income
$12,645.22
Full CQP calculator →

Portfolio growth — MRK vs CQP

📍 CQP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRKCQP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRK + CQP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRK pays
CQP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
CQP
Annual income on $10K today (after 15% tax)
$417.91/yr
After 10yr DRIP, annual income (after tax)
$10,748.44/yr
At 15% tax rate, CQP beats the other by $2,151.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRK + CQP for your $10,000?

MRK: 50%CQP: 50%
100% CQP50/50100% MRK
Portfolio after 10yr
$61.7K
Annual income
$11,379.50/yr
Blended yield
18.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
CQP
Analyst Ratings
3
Buy
5
Hold
10
Sell
Consensus: Sell
Price Target
$47.50
-29.2% upside vs current
Range: $44.00 — $55.00
Altman Z
2.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRK buys
0
CQP buys
0
No recent congressional trades found for MRK or CQP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRKCQP
Forward yield2.81%4.92%
Annual dividend / share$3.32$3.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR32.7%25.3%
Portfolio after 10y$57.7K$65.7K
Annual income after 10y$10,113.78$12,645.22
Total dividends collected$29.8K$39.5K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuySell
Analyst price target$128.54$47.50

Year-by-year: MRK vs CQP ($10,000, DRIP)

YearMRK PortfolioMRK Income/yrCQP PortfolioCQP Income/yrGap
1← crossover$11,213$373.04$11,316$616.05$103.00CQP
2$12,667$512.06$12,925$816.35$258.00CQP
3$14,439$708.14$14,921$1,091.85$482.00CQP
4$16,640$988.16$17,442$1,476.10$802.00CQP
5$19,432$1,394.07$20,683$2,020.55$1.3KCQP
6$23,057$1,992.90$24,937$2,805.86$1.9KCQP
7$27,889$2,894.79$30,644$3,961.48$2.8KCQP
8$34,518$4,286.29$38,490$5,700.69$4.0KCQP
9$43,912$6,494.35$49,569$8,384.84$5.7KCQP
10$57,714$10,113.78$65,684$12,645.22$8.0KCQP

MRK vs CQP: Complete Analysis 2026

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

CQPStock

Cheniere Energy Partners, L.P., through its subsidiaries, owns and operates natural gas liquefaction and export facility at the Sabine Pass liquefied natural gas (LNG) terminal located in Cameron Parish, Louisiana. The company's regasification facilities include five LNG storage tanks with an aggregate capacity of approximately 17 billion cubic feet equivalent; two marine berths that accommodate vessels with capacity of up to 266,000 cubic meters; and vaporizers with regasification capacity of approximately 4 billion cubic feet per day. It also owns a 94-mile pipeline that interconnects the Sabine Pass LNG terminal with various interstate pipelines. Cheniere Energy Partners GP, LLC serves as the general partner of the company. The company was founded in 2003 and is headquartered in Houston, Texas.

Full CQP Calculator →
📬

Get this MRK vs CQP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRK vs JNJMRK vs ABBVMRK vs PFEMRK vs BMYMRK vs LLYMRK vs SCHDMRK vs JEPIMRK vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.